Ipsen Pharmaceuticals

A ballpoint pen rests on top of a stack of documents ready for signing
Biotech

Ipsen's ADC push leads to $1B deal for preclinical Simcere drug

Ipsen may be a recent entrant into the antibody-drug conjugate space, but the French biopharma is continuing to make up for lost time.
James Waldron Dec 22, 2025 7:15am
saker falcon

Ipsen fails to land pivotal rare disease trial

Dec 19, 2025 3:37pm
Illustration connected puzzle pieces with the acronym MA

Ipsen inks €1B buyout of French biotech ImCheck

Oct 22, 2025 10:33am
liver disease fibrosis NASH NAFLD cancer cirrhosis liver

Zydus' phase 3 win tees up filing to challenge Gilead and Ipsen

Aug 29, 2025 10:59am
illustration of two arrows going in opposite directions

Ipsen hands back Sutro's ROR1 ADC at center of $875M deal

Aug 8, 2025 6:15am
image of two race cars neck and neck

Ipsen joins ADC race via $900M biobuck deal with Sutro

Apr 2, 2024 7:26am